Back Bay Life Science Advisors to Lead Panel Discussion with Myovant Sciences President & Chief Executive Officer, Lynn Seely at Convergence Forum 2018

Back Bay Life Science Advisors will again serve as a lead sponsor for the Convergence Forum. On May 11, Back Bay CEO Jonathan Gertler will host a discussion with former Medivation Founder and current Myovant Sciences President & Chief Executive Officer, Lynn Seely.


Back Bay Celebrates 8 Years and 450 Life Science Assignments

By Jonathan P. Gertler
Back Bay’s first day was April 8, 2010. In those days, we occupied a small walk-up office on Newbury Street in Boston. Today, we are 450 BioPharma and MedTech assignments more experienced, 30 life science experts strong and operate globally from an entire floor of bright offices overlooking the Boston skyline. All this, as we get ready to celebrate our eighth birthday. Thank you to all who have made this growth possible and for the privilege of working alongside you.


Danish Life Science Leaders and US Investors to Meet on Cross-Border Development

DKBIO 2018, Sponsored by the Consulate General of Denmark and Back Bay Life Science Advisors, will Highlight Global Innovation and Collaboration in Biotech

BOSTON, MA, March 28, 2018 – Back Bay Life Science Advisors today announces that it is co-sponsoring DKBIO 2018: Danish Science and the City. For the first time in Boston, 17 leading Danish life science companies will convene with top-tier American life science investors and scientific collaborators on April 10 – 11 at Harvard Medical School to discuss cross-border development between biotech communities in Copenhagen and Boston.


Back Bay CEO Quoted in Xconomy

RE: Jonathan P. Gertler

Back Bay CEO Jonathan Gertler was recently quoted in an article titled, “Proxima Aims to Fill CRO Gap for Houston’s Growing Biotech Community,” published in Xconomy and syndicated by Pharmacy Choice.

The article profiles the company Proxima and highlights the importance of contract research organizations (CROs) in bridging the gap between life science companies and clinical trial services.


Back Bay CEO Authors Article for Life Science Leader

RE: Jonathan P. Gertler

Back Bay CEO Jonathan Gertler recently penned “The Dynamics And Value Of Cross-Border Biotech” for Life Science Leader. In it, Dr. Gertler explores the globalization of biotech in relation to the robust Danish biotech sector.


Biosimilars: The Cure for Sky-High Drug Prices or a Stake in the Heart of Innovation?

/ Biosimilars, Biotech, Michelle Hoffmann
By Michelle Hoffmann

Back Bay Life Science Advisors Senior Vice President, Michelle Hoffmann, wrote a piece for STAT’s “first opinion” section on the U.S. biosimilar market. Titled, “Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?” the piece explains the history of U.S. biosimilars and details what the future may hold.

What Should Be Done About the Shrinking Number of US Public Companies?

By: Greg Benning

Back Bay Insights on JP Morgan 2018 Market Outlook; Inflection Point Investing

JP Morgan’s recently published Eye on the Market Outlook 2018 The Decline of Western Centralization is a cleverly-titled economic research piece focused on the implications of unwinding a 9-year, $11 trillion central bank stimulus effort.  (more…)

Back Bay Life Science Advisors CEO Jonathan Gertler Helps Healthcare Companies Grow

RE: Jonathan P. Gertler

Back Bay Life Science Advisors CEO Jonathan Gertler spoke with FierceCEO about growth, innovation and the joy of simultaneously leading and working for great people.

In “Back Bay Life Science Advisors CEO Jonathan Gertler helps healthcare companies grow,” Gertler describes Back Bay’s role in advancing new healthcare technologies to help life science companies improve.


US Biosimilars 2018: Opportunities and Challenges

RE: Jonathan P. Gertler

As we start a new year, we would like to share Back Bay’s latest thought piece, US Biosimilars: Opportunities and Challenges.  Researched and written by Michelle Hoffmann, PhD and Jon Barry, MD, the insights are substantive, with calculated optimism.

Read the Whitepaper

MedCity News: Back Bay’s Christopher Leo Shares Perspective on the Reproductive Health Genetic Testing Market

RE: Christopher Leo

Back Bay Life Science Advisors Senior Vice President of Strategy Consulting, Christopher Leo, wrote a piece for MedCity News around the burgeoning reproductive health genetic testing market.